Abstract
The aims of treatment of patients with heart failure with reduced ejection fraction (HFrEF) are, on one hand, to improve both mortality and morbidity, on the other hand to improve patient's quality of life. In the PARADIGM-HF study, the dual neurohumoral inhibitor sacubitril/valsartan decreased both the total mortality by 16% and the cardiovascular mortality by 20% more than ACE inhibitor enalapril.
It was also significantly more effective in improving the quality of life. Compared to enalapril, it significantly decreased not only the number of hospitalizations for worsening heart failure but also the number of episodes of heart failure worsening treated in the ambulatory setting.
Complex evaluation of HFrEF patientʼs quality of life using disease-specific questionnaire (KCCQ) has shown that sacubitril/valsartan decreased the limitations of physical and social activities as a result of heart failure significantly more than enalapril.